Temaz and Keytruda drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Temaz (temazepam) and Keytruda (pembrolizumab). Common drug interactions include decreased appetite among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Temaz and Keytruda. It is created by eHealthMe based on reports of 29 people who take the same drugs from the FDA, and is updated regularly.

What is Temaz?

Temaz has active ingredients of temazepam. It is often used in insomnia. eHealthMe is studying from 42,293 Temaz users. Check the latest studies of Temaz.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 16, 2026

29 people who take Temaz and Keytruda together, and have interactions are studied.

What are the common drug interactions of Temaz and Keytruda, by gender? *:

female:

Decreased appetite
Dehydration (dryness resulting from the removal of water)
Pneumonia
Abdominal pain upper
Asthenia (weakness)
Back pain
Blood glucose increased
Confusional state
Constipation
Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)

male:

Death
Adverse event
Vitreous floaters (spots before the eyes)
Weight decreased
Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
Chills (felling of cold)
Constipation
Dizziness
Fatigue (feeling of tiredness)
Hot flush (sudden feelings of heat)

What are the common drug interactions of Temaz and Keytruda, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Adverse event
Death

30-39:

n/a

40-49:

n/a

50-59:

Death
Deafness bilateral
Encephalitis (inflammation of the brain)
Hepatotoxicity (chemical-driven liver damage)

60+:

Decreased appetite
Dehydration (dryness resulting from the removal of water)
Dyspepsia (indigestion)
Fatigue (feeling of tiredness)
Glossodynia (a burning or painful sensation in the tongue)
Intervertebral disc protrusion (spinal disc protrusion)
Nausea (feeling of having an urge to vomit)
Vomiting
Weight decreased
Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)

What are the existing conditions these people have? *

Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 3 people, 10.34%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 3 people, 10.34%
Lung Cancer - Non-Small Cell (lung cancer): 3 people, 10.34%
Endometrial Cancer: 3 people, 10.34%
Lung Cancer - Small Cell (lung cancer): 2 people, 6.90%
Back Pain: 2 people, 6.90%

* Approximation only. Some reports may have incomplete information.

Do you take Temaz and Keytruda?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously